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Background
As combined antiretroviral therapy has allowed patients
infected with HIV to survive longer due to improved
immunity, increasing incidences of non-AIDS associated
malignancies as well as chronic comorbidities are
r e p o r t e d .O n eo ft h em o r ec o m m o n l yr e p o r t e dn o n -
AIDS associated cancers is Hodgkin’sl y m p h o m a( H L )
[1]. We report our experience of HL among HIV-
infected and uninfected patients.
Methods
Grady Health System (GHS) provides care to the major-
ity of the urban indigent population of Atlanta. Patients
who were diagnosed with HL between January 2000 and
June 2011were identified from the GHS pathology
records and the GHS cancer registry. Clinic charts and
medical records were reviewed. Patients’ demographics,
CD4 counts, HIV viral load, HIV and HL treatment and
outcomes were recorded.
Results
During the study period, 95 patients were diagnosed
with HL (26% HIV-, 30% HIV+ and 43% HIV status
unknown). The characteristics are displayed in Table 1.
Among the HIV+ patients, at time of HL diagnosis,
the median Cd4 at time of HL diagnosis was 95(8-865)
cells/mm
3, and 3 (10%) are on cART .The median time
from HIV diagnosis to HL diagnosis is 2 years (0-20).
Conclusions
In the current cART era, in our institution, HL in HIV+
patients is more likely to present with advanced disease
(65% with stage III/IV). Interestingly, in 3 HIV+ patients,
HL was diagnosed solely by bone marrow biopsy. Despite
the availability of cART, patients are not accessing care.
This may account for the poor one-year survival among
HIV+ patients with HL.
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Table 1 Characteristics of HL in HIV- and HIV + patients
HIV- HIV+
N2 5 2 9
M:F 16:9 22:7
Race (black:other) 20:5 25:4
Median age (range) 33(19-52) 40(22-54)
Stage (I-II versus III-IV) 5:9 2:19
B symptoms 4 5
Diagnosis made solely by bone marrow biopsy 0 3
Morphology NS/LR versus MC/LD 12:5 9:2
One year survival 76% 45%
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